Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
NPY is involved in various neurological processes and neuropsychiatric disorders, including fear learning and anxiety disorders.
|
31708112 |
2020 |
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, genetic mouse models in combination with novel neuron-controlling chemogenetic and optogenetic technologies have also uncovered additional functions for this Arc NPY population that go beyond the simple food intake stimulatory action and link these NPY neurons to the control of energy expenditure, thermogenesis, physical activity, food-seeking behavior, and anxiety.
|
31089694 |
2019 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Two weeks after SPS, intranasal NPY at 300 µg/rat, but not 150 µg which was effective after one week, reversed SPS triggered elevated anxiety.
|
30878321 |
2019 |
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Decrease in NPY and PV expression in the hippocampus may explain the possible mechanism of hyperandrogenization induced anxiety.
|
31281833 |
2019 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Although NPY has potent anxiolytic actions within the BLA, selective activation of BLA NPY Y<sub>2</sub> receptors (Y<sub>2</sub>Rs) acutely increases anxiety by an unknown mechanism.
|
30971438 |
2019 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We analyzed the modulation of calcitonin gene-related peptide (CGRP; exerting anxiogenic effects in BNST), neuropeptide Y (NPY; exerting mainly anxiolytic effects), and microglia activation (neuroinflammation marker, thought to increase anxiety).
|
31114482 |
2019 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings support the conclusion that alterations in both hippocampal NPY and MC4R expression are involved in anxiety level changes in rats, while their quantitative relationship (NPY/MC4R ratio) is even more valuable in the estimation of anxiety regulation than individual alterations for both NPY and MC4R expression in the hippocampus.
|
30863280 |
2019 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
However, the role of GABA release from NPY+ interneurons in adolescent anxiety is unclear.
|
30024942 |
2018 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide Y (NPY) receptors belong to the G-protein-coupled receptor superfamily and have important roles in food intake, anxiety and cancer biology <sup>1,2</sup> .
|
29670288 |
2018 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we present an overview of findings with regard to the NPY system in relation to anxiety and stress, acute as well as chronic; furthermore we discuss post-traumatic stress disorder and, in part depression.
|
28824541 |
2017 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Several reports have demonstrated that neuropeptide Y (NPY) is involved in food intake, epilepsy, circadian rhythms, drug seeking, pain and anxiety, and other physiological or pathological conditions.
|
29042065 |
2017 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
By demonstrating that NPY release modulates hippocampal synaptic plasticity and is impaired by predator scent stress, our results provide a novel mechanism by which stress-induced anxiety alters circuit function.
|
28053027 |
2017 |
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Increased melanocortin and decreased neuropeptide Y activity due to changes in histone acetylation in emotional brain circuitry may play a role in adolescent intermittent ethanol-induced anxiety phenotypes in adulthood.
|
28575455 |
2017 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Substantial preclinical evidence supports the role of NPY in the modulation of stress response and in the regulation of anxiety in animal models.
|
27913193 |
2017 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Galanin (GAL) and neuropeptide Y (NPY) are neuropeptides involved in behaviors associated with anxiety.
|
24841617 |
2015 |
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, alterations in anxiety- and depression-regulating genes were present in the hypothalamus of BACHD mice including reduced mRNA expression of neuropeptide Y, tachykinin receptor 3 and vesicular monoamine transporter type 2 as well as increased expression of cocaine and amphetamine regulated transcript.
|
23697793 |
2013 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
NPY has recently gained much attention as an endogenous antiepileptic and antidepressant agent, as drugs with antiepileptic and/or mood-stabilizing properties may exert their action by increasing NPY concentrations, which in turn can reduce anxiety and depression levels, dampen seizures or increase seizure threshold.
|
23994577 |
2013 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
This differential genetic modulation of NPY stress response was suppressed in the SD group, who showed no stress-related increases in NPY and higher heart rate and greater anxiety, regardless of diplotype.
|
21917383 |
2012 |
Anxiety Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion, we provide further support for involvement of mainly GAD1, but also NPY in determining predisposition to anxiety disorders.
|
22328461 |
2012 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
CCK interacts with several anxiety-relevant neurotransmitters such as the serotonergic, GABA-ergic and noradrenergic system as well as with endocannabinoids, NPY and NPS.
|
22553078 |
2012 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
NPY has been attributed a central role in anxiety-like behavior, fear, nociception, and reward in rodents.
|
22938859 |
2012 |
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide Y (NPY) has been found to play a role in the pathomechanism of both anxiety and depression.
|
19854625 |
2010 |
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A recent study found NPY expression to be inversely correlated with trait anxiety.
|
20037921 |
2010 |
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
There is extensive evidence, from both clinical cases and rodent models, for reduced levels of the widely expressed neuropeptide Y (NPY) in anxiety and depressive disorders.
|
19264362 |
2009 |
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here we show that the claims of Zhou et al. that neuropeptide Y (NPY) diplotype-predicted expression is correlated with trait anxiety (neuroticism) is not replicated in a data set consisting of phenotypically extreme individuals drawn from a large (n = 88,142) non-clinical population.
|
19340021 |
2009 |